AIDS Research Alliance

AIDS Research Alliance of America
Founded	1989
Location	Los Angeles, California;
Area served	United States
Key people	Carolyn H. Carlburg, J.D., Chief Executive Officer Stephen J. Brown, M.D., Medical Director
Website	AIDS Research Alliance: Home

AIDS Research Alliance of America (ARAA) was a national community-based 501(c)(3) non-profit medical research institution that sought to develop a cure for HIV/AIDS, medical strategies to prevent new HIV infections and better treatments for people living with HIV/AIDS.^[1] From 1989 to 2015, ARAA conducted over 150 clinical and pre-clinical studies,^[2] ranging from alternative therapies^[3]^[4]^[5] that employed a complementary approach to HIV care to the first in-human HIV vaccine trial.^[6] AIDS Research Alliance was partly responsible for "fast-tracking" to market half of today's anti-HIV treatments.

^ "CenterWatch Research Center Profile Pages". Centerwatch.com. Archived from the original on February 14, 2012. Retrieved January 12, 2012.
^ "CenterWatch". Search.centerwatch.com. Retrieved January 12, 2012.
^ J Kaiser; J Ondercin; G Santos; G Leoung; S Brown; M Mass; M Baum (February 8–11, 2004). Broad-Spectrum Micronutrient Supplementation in HIV-infected Patients With Dideoxynucleoside-related Peripheral Neuropathy: A Prospective, Double-Blind, Placebo Controlled Trial (PDF). 11th Conference on Retroviruses and Opportunistic Infections. San Francisco. Archived from the original (PDF) on March 21, 2006.
^ "Foundation for Integrative AIDS Research Report on the 11th Conference on Retroviruses and Opportunistic Infections, February 2004". Fiar.us. February 10, 2004. Retrieved January 12, 2012.
^ Bergner, Paul (2001). "Allium sativum: Antibiotic and Immune Properties". Medical Herbalism. North American Institute of Medical Herbalism. Archived from the original on August 17, 2004. Retrieved February 23, 2013.
^ Brown SJ; Harro C; Mayer KH; Bartholow BN; Buchbinder S; Mastro TD; Judson F; Gorse GJ; et al. (July 2003). VaxGen AIDSVAX B/B Vaccine Trial: Recruitment, Demographics, and Changes in Risk Behaviors - Lessons for Future Trials. National HIV Prevention Conference. Atlanta, Georgia, United States. T3-D0502. Retrieved February 23, 2013.{{cite conference}}: CS1 maint: numeric names: authors list (link)

[1] "CenterWatch Research Center Profile Pages". Centerwatch.com. Archived from the original on February 14, 2012. Retrieved January 12, 2012.

[2] "CenterWatch". Search.centerwatch.com. Retrieved January 12, 2012.

[3] J Kaiser; J Ondercin; G Santos; G Leoung; S Brown; M Mass; M Baum (February 8–11, 2004). Broad-Spectrum Micronutrient Supplementation in HIV-infected Patients With Dideoxynucleoside-related Peripheral Neuropathy: A Prospective, Double-Blind, Placebo Controlled Trial (PDF). 11th Conference on Retroviruses and Opportunistic Infections. San Francisco. Archived from the original (PDF) on March 21, 2006.

[4] "Foundation for Integrative AIDS Research Report on the 11th Conference on Retroviruses and Opportunistic Infections, February 2004". Fiar.us. February 10, 2004. Retrieved January 12, 2012.

[CITEREF_bergner2001-5] Bergner, Paul (2001). "Allium sativum: Antibiotic and Immune Properties". Medical Herbalism. North American Institute of Medical Herbalism. Archived from the original on August 17, 2004. Retrieved February 23, 2013.

[6] Brown SJ; Harro C; Mayer KH; Bartholow BN; Buchbinder S; Mastro TD; Judson F; Gorse GJ; et al. (July 2003). VaxGen AIDSVAX B/B Vaccine Trial: Recruitment, Demographics, and Changes in Risk Behaviors - Lessons for Future Trials. National HIV Prevention Conference. Atlanta, Georgia, United States. T3-D0502. Retrieved February 23, 2013.{{cite conference}}: CS1 maint: numeric names: authors list (link)

[1]

[2]

[3]

[4]

[5]

[6]